Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson’s Disease

AI Briefing

• – Vima Therapeutics announces Phase 2 trial start for VIM0423 in isolated dystonia, with $100M in Series A funding to advance oral therapy for dystonia and Parkinson's disease.
• – Vima Therapeutics to initiate Phase 2 trial in Parkinson's disease in mid-2026, with topline data expected in 2027.
• – Joe Cabral joins Vima's Board of Directors as part of $100M Series A financing round.